Verona Pharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update OhtuvayreTM (ensifentrine) now available; patient shipments started Strong balance sheet supports commercialization and pipeline expansion Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST ...

Verona Pharma to Present at 44th Annual Canaccord Growth Conference LONDON and RALEIGH, N.C., July 30, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at...

Verona Pharma to Report Second Quarter 2024 Financial Results and Provide Corporate Update LONDON and RALEIGH, N.C., July 25, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the second...

Verona Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update PDUFA Target Action Date for Ensifentrine of June 26, 2024  Finalizing commercial launch preparations Strong balance sheet supports commercialization and pipeline expansion Conference call today at...

Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024 Verona Pharma plc to present additional analyses of positive Phase 3 ENHANCE studies in COPD at ATS 2024.